Takimoto Chris H 4
4 · IGM Biosciences, Inc. · Filed Jun 18, 2024
Insider Transaction Report
Form 4
Takimoto Chris H
Chief Medical Officer
Transactions
- Sale
Common Stock
2024-06-14$7.58/sh−1,570$11,893→ 95,818 total - Award
Common Stock
2024-05-15$5.02/sh+3,000$15,060→ 97,388 total
Footnotes (3)
- [F1]The shares were acquired under the IGM Biosciences, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
- [F3]This transaction was executed in multiple trades at prices ranging from $7.26 to $7.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.